JP2021529518A5 - - Google Patents

Info

Publication number
JP2021529518A5
JP2021529518A5 JP2020572386A JP2020572386A JP2021529518A5 JP 2021529518 A5 JP2021529518 A5 JP 2021529518A5 JP 2020572386 A JP2020572386 A JP 2020572386A JP 2020572386 A JP2020572386 A JP 2020572386A JP 2021529518 A5 JP2021529518 A5 JP 2021529518A5
Authority
JP
Japan
Prior art keywords
donor polynucleotide
mutation
item
strand
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572386A
Other languages
English (en)
Japanese (ja)
Other versions
JP7550057B2 (ja
JP2021529518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000833 external-priority patent/WO2020003006A2/en
Publication of JP2021529518A publication Critical patent/JP2021529518A/ja
Publication of JP2021529518A5 publication Critical patent/JP2021529518A5/ja
Application granted granted Critical
Publication of JP7550057B2 publication Critical patent/JP7550057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572386A 2018-06-28 2019-06-28 ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法 Active JP7550057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691573P 2018-06-28 2018-06-28
US62/691,573 2018-06-28
PCT/IB2019/000833 WO2020003006A2 (en) 2018-06-28 2019-06-28 Compositions and methods for genomic editing by insertion of donor polynucleotides

Publications (3)

Publication Number Publication Date
JP2021529518A JP2021529518A (ja) 2021-11-04
JP2021529518A5 true JP2021529518A5 (https=) 2022-06-20
JP7550057B2 JP7550057B2 (ja) 2024-09-12

Family

ID=68242754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572386A Active JP7550057B2 (ja) 2018-06-28 2019-06-28 ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法

Country Status (12)

Country Link
US (3) US11827877B2 (https=)
EP (1) EP3814499A2 (https=)
JP (1) JP7550057B2 (https=)
KR (1) KR20210027389A (https=)
CN (1) CN112585268B (https=)
AU (1) AU2019293286A1 (https=)
BR (1) BR112020025824A2 (https=)
CA (1) CA3104028A1 (https=)
IL (1) IL279718A (https=)
MX (1) MX2020014248A (https=)
SG (1) SG11202012499RA (https=)
WO (1) WO2020003006A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
BR112018008971A2 (pt) 2015-11-06 2018-11-27 Crispr Therapeutics Ag materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
AU2019293286A1 (en) 2018-06-28 2021-01-07 Crispr Therapeutics Ag Compositions and methods for genomic editing by insertion of donor polynucleotides
SG11202103917VA (en) * 2018-10-16 2021-05-28 Blueallele Llc Methods for targeted insertion of dna in genes
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
US20220056437A1 (en) * 2020-08-19 2022-02-24 Integrated Dna Technologies, Inc. Methods and compositions for inhibition of crispr re-cleavage events
US20240368587A1 (en) * 2021-04-01 2024-11-07 Duke University Compositions For and Methods of Editing the Genome
CN113403309B (zh) * 2021-05-24 2022-08-16 珠海舒桐医疗科技有限公司 非同源双链寡聚核苷酸片段在基因敲除系统中的应用
CN113416730B (zh) * 2021-07-07 2023-04-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种降低细胞因基因编辑产生的大片段删除突变的方法
EP4504947A4 (en) * 2022-04-07 2026-03-25 Univ Duke COMPOSITIONS AND METHODS TO PROMOTE LIVER REGENERATION BY GENE EDITING IN METABOLIC LIVER DISEASE
WO2023201276A2 (en) * 2022-04-12 2023-10-19 Orthobio Therapeutics, Inc. Lipid nanoparticles for gene editing systems
CN114686440B (zh) * 2022-05-31 2022-09-27 南京艾尔普再生医学科技有限公司 一种低免疫原性iPSC细胞的制备方法、低免疫原性iPSC细胞及组合物
WO2024215891A1 (en) * 2023-04-11 2024-10-17 The General Hospital Corporation Methods for nucleic acid labeling
CN117953969B (zh) * 2023-12-18 2024-08-27 广州凯普医学检验所有限公司 一种线粒体疾病预测方法及线粒体疾病预测系统

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション オリゴヌクレオチド n‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5031272A (en) 1990-02-28 1991-07-16 Carmien Joseph A Tool handle and method of attaching a handle to a percussive tool head
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
MY107332A (en) 1990-08-03 1995-11-30 Sterling Drug Inc Compounds and methods for inhibiting gene expression.
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド サイエンシズ,インコーポレイテッド 改変ヌクレオシド間結合
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
DE10328289B3 (de) 2003-06-23 2005-01-05 Enginion Ag Arbeitsmedium für Dampfkreisprozesse
US9163262B2 (en) 2003-12-17 2015-10-20 The Catholic University Of America In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
GB0816778D0 (en) * 2008-09-12 2008-10-22 Isis Innovation Gene silencing
EP2456877A4 (en) 2009-07-24 2012-05-30 Sigma Aldrich Co Llc METHOD OF GENOMIC PROCESSING
CN102858985A (zh) 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
EP2703491B1 (en) 2010-04-09 2017-03-08 The Catholic University Of America Protein and nucleic acid delivery vehicles, components and mechanisms thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性hsvベクター及びその製造のための補完細胞
AU2014354839B2 (en) 2013-11-26 2020-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors for treatment of glycogen storage disease
US20160314245A1 (en) 2014-06-17 2016-10-27 Genepeeks, Inc. Device, system and method for assessing risk of variant-specific gene dysfunction
AU2016344609B2 (en) 2015-10-28 2022-05-12 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of duchenne muscular dystrophy
BR112018008971A2 (pt) 2015-11-06 2018-11-27 Crispr Therapeutics Ag materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
CN109715801B (zh) * 2015-12-01 2022-11-01 克里斯普治疗股份公司 用于治疗α1抗胰蛋白酶缺乏的材料和方法
WO2018096356A1 (en) 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
WO2019239361A1 (en) 2018-06-14 2019-12-19 Novartis Ag Method for sequence insertion using crispr
AU2019293286A1 (en) * 2018-06-28 2021-01-07 Crispr Therapeutics Ag Compositions and methods for genomic editing by insertion of donor polynucleotides

Similar Documents

Publication Publication Date Title
JP2021529518A5 (https=)
CN113994000B (zh) 包括胞苷类似物的反义rna编辑寡核苷酸
US12545912B2 (en) CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US20220127609A1 (en) Antisense oligonucleotides for nucleic acid editing
US20230323346A1 (en) Antisense oligonucleotides for rna editing
US20220340900A1 (en) Chemically modified oligonucleotides for rna editing
US20240229030A9 (en) Nucleic acid molecules for pseudouridylation
CN108350454B (zh) 等位基因选择性基因编辑及其用途
US20230332184A1 (en) Template guide rna molecules
WO2021178709A1 (en) Methods and compositions for modulating a genome
CN106459995A (zh) 使用统治型gRNA的CRISPR相关方法和组合物
EP3129485A2 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
KR20240023081A (ko) CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도
BR112020025824A2 (pt) composições e métodos para edição genômica por inserção de polinucleotídeos doadores
CN118043457A (zh) 用于插入和编辑大核酸片段的系统和方法
TW202417017A (zh) 具有化學修飾的導引rna
Balke et al. In vitro repair of a defective EGFP transcript and translation into a functional protein
KR102638799B1 (ko) CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도
KR20230016751A (ko) 염기 편집기 및 이의 용도
WO2025039972A9 (en) Tls-based gene editing systems
WO2019194320A1 (ja) エンジニアリングされたBlCas9ヌクレアーゼ
WO2024220934A1 (en) Nucleic acid molecules for pseudouridylation
CN120501894A (zh) 一种用于治疗α-地中海贫血的组合物及其应用
CN116568806A (zh) 用于增加crispr/cas12f1(cas14a1)系统的效率的经工程化的引导rna及其用途
HK1233299B (en) Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa